CytomX Therapeutics, Inc.

CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment. The company develops conditionally activated oncology candidates across modalities including T-cell engagers, antibody-drug conjugates, cytokines, immunotherapies, and mRNA, and it also partners its platform with large pharma companies to fund development and broaden reach.

−27,8 %

−22,8 %

−44,8 %

3.09

3.09

— CytomX Therapeutics, Inc.
%
PROBODY platform0% Masked biologic technology that conditionally activates therapeutic candidates in diseased tissue.
Partnered collaboration programs70% Research, license, and milestone-based programs with large biopharma partners.
Wholly owned oncology pipeline20% Internal drug candidates advanced by CytomX, including CX-2051 and preclinical assets.
Platform-enabled discovery services10% Collaborative R&D work that generates upfront, milestone, and reimbursement revenue.

CytomX's direct customers are not patients or hospitals; they are pharmaceutical and biotechnology partners that...

  • Large pharmaceutical partnersprimary

    Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna fund and advance partnered programs through collaboration, milestone, and license structures.

  • Biotechnology collaboratorsprimary

    Smaller and mid-sized biotech firms use the PROBODY platform to access masked biologic design capabilities and oncology development support.

  • Internal oncology pipelinesecondary

    CytomX itself is the end user of its platform for wholly owned programs such as CX-2051 and CX-908.

  • Future commercial oncology patientsemerging

    If candidates are approved, cancer patients would be the eventual end market for the company's therapies.

CytomX is headquartered in the United States and operates as a U.S.-based clinical-stage biotech with research and...

  • •Headquartered in the United States
  • •Partner base includes global pharma companies
  • •Revenue is collaboration-driven rather than product-sales driven
  • •No approved products or disclosed commercial geography mix
  • •Dependent on third-party manufacturing and clinical supply networks

CytomX is prioritizing its most promising internal asset, CX-2051, while continuing to use partnerships to extend the...

01
Focus capital on CX-2051short-term

Concentrating resources on the lead wholly owned program improves the chance of creating a value-driving clinical asset.

02
Expand partnered masked T-cell engager programsmedium-term

Partnering lowers development cost while extending the platform into a high-interest oncology modality.

03
Broaden PROBODY across multiple modalitieslong-term

Applying masking technology to ADCs, cytokines, and mRNA increases the addressable pipeline and partnering opportunities.

CytomX faces the classic risks of a clinical-stage biotech: no approved products, recurring losses, and dependence on...

high

Lack of approved products and product revenue

The company is still clinical-stage, so it depends on collaboration revenue and future approvals that may never occur.

Scope
All programs
Materiality
high
high

Liquidity and financing risk

Operating losses and R&D spending require external capital; management said existing resources fund operations only into Q2 2026.

Scope
Corporate
Materiality
high
high

Partner concentration and program termination

Revenue and development progress depend on a small number of collaboration partners and their budget priorities.

Scope
Amgen, Astellas, BMS, Regeneron, Moderna
Materiality
high
high

Clinical and regulatory development risk

Preclinical and clinical candidates may fail to show efficacy, safety, or manufacturability required for approval.

Scope
CX-2051, CX-904, CX-908, CX-801
Materiality
high
medium

Competitive pressure in oncology platforms

Large pharma and biotech peers are developing competing ADC, TCE, masking, and immuno-oncology products.

Scope
PROBODY platform and pipeline
Materiality
high
Over-time collaboration revenue recognition
Affects reported revenue and quarterly comparability
Variable consideration and milestones
Can create lumpy revenue from partner achievements
Restructuring charges
Impacts near-term margins and liquidity
Tax valuation allowances and NOLs
Can affect effective tax rate and balance sheet presentation

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

Sionna Therapeutics, Inc.

SION · Pharmaceutical Preparations

CytoDyn Inc.

CYDY · Pharmaceutical Preparations

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

CITIUS ONCOLOGY, INC.

CTOR · Pharmaceutical Preparations

: 28.4.2026